aod9604 fat loss efficacy side effects AOD-9604 (10mg vials) Understanding AOD 9604: The Science

NNMT inhibition as a therapeutic strategy has been explored in industry pharmaceutical pipelines (including a Pfizer program for non-alcoholic fatty liver disease that was reportedly discontinued in early clinical development), but no NNMT inhibitor has reached regulatory approval to date

Lower NAD+ means reduced sirtuin activity (SIRT1, SIRT3), which further impairs mitochondrial function and fatty acid oxidation in fat cells

Steady state (Weeks 38): Continue the same daily dose

Obese individuals may require doses at the higher end of the range, though this should be done under medical supervision

Click here if you are not automatically redirected after 5 seconds.